Unlike GIP, the action of GLP-1 is preserved in patients with type 2 diabetes. Glucagon-like peptide-1 receptor agonists gained approval as drugs to treat diabetes and obesity starting in the 2000s.
GLP-1 receptor agonists (GLP-1-RA) are emerging as promising agents beyond their established role in type 2 diabetes mellitus (T2DM) and obesity treatment, showing significant nephroprotective effects.
GLP-1 receptor agonists represent an expanding class of therapeutics with significant non-neurodegenerative potential across vascular, sleep-related, intracranial pressure, and headache disorders.
Table 5. GLP-1 Receptor Agonist Dosing in Patients with Renal Impairment[23]. *Hypovolemia due to nausea/vomiting may worsen renal function CrCl = creatinine clearance; ESRD = end-stage renal disease.
GLP-1 was first characterized as a peripheral incretin hormone regulating insulin secretion and appetite. Subsequent work established that GLP-1 receptors are also expressed in the central nervous system, particularly in regions central to reward processing...
Dosing adjustments for GLP-1 receptor agonists (GLP-1RAs) are crucial in optimizing treatment for patients with type 2 diabetes and obesity. Different GLP-1RAs possess varied dosing frequencies, with some administered daily while others are once weekly.
GLP-1 receptor agonists appear to modulate nearly all of these components; the mechanisms underlying their blood pressure-lowering effects are illustrated in Fig.GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest.
GLP-1 microdosing involves using significantly lower, sustained doses of GLP-1 receptor agonists such as semaglutide or tirzepatide than those typically recommended in the manufacturer's official dosing schedule.
GLP-1 receptor on the endocardium (top), the cardiomyocytes (middle), and in the vessel wall of a mesenterial artery (bot-. tom). (Modified from [23].)tes patients with stable coronary artery disease. Am J.
